En Es
Categories

Industry News

AI-Based Mammography Software Receives FDA Clearance

By Medimaging International staff writers
05 Apr 2019

Image: The cmTriage software enables a radiologist to customize, sort, and prioritize their mammography worklist based on cases that may need immediate attention (Photo courtesy of CureMetrix).CureMetrix (La Jolla, CA, USA) has received clearance from the US Food and Drug Administration to market cmTriage, a workflow optimization tool that enables a radiologist to customize, sort, and prioritize their mammography worklist based on cases that may need immediate attention.

CureMetrix is a healthcare technology company that develops computer-aided detection (CAD) software based on artificial intelligence (AI) for medical image analysis. Instead of today’s method of first in, first out for reading through a screening mammography worklist, radiologists can now use CureMetrix cmTriage to identify which cases are suspicious and focus on those first. They can also use cmTriage to optimize their clinical workflow by sending the suspicious cases to their most senior radiologists or reading the suspicious cases immediately before the patient has even left the clinic. CureMetrix cmTriage has an area under the curve (AUC) of 0.95. With this high level of efficacy, radiologists can expect cmTriage to highlight the suspicious cases without excessive false positives.

“Early and accurate detection in breast cancer is key in improving cancer survival rates worldwide through the development of next generation medical image analysis solutions. With 40 million mammograms a year in the US, only five cancers per 1,000 are being found at screening. cmTriage allows the radiologist to prioritize their worklist, creating the potential to help doctors move more quickly through their reviews and find those cancers by highlighting the suspicious cases. “Our ability to bring cmTriage to the medical community is a major milestone in our mission to deliver CAD that Works to support the radiologist and the patients they serve,” said Kevin Harris, CEO and Board Director for CureMetrix.

“Our goal is to provide radiologists with analytic tools to enhance diagnosis in breast cancer screening and augment treatment decisions,” said Lisa Watanabe, M.D., Chief Medical Officer at CureMetrix and Clinical Associate Professor at University of Southern California. “On average, early signs of breast cancer may be missed up to 50% of the time on mammograms. Analysis of mammograms with cmTriage has the potential to help radiologists focus on the suspicious cases and increase their productivity. This will allow for more time to engage with our patients and the healthcare team. Providing radiologists with the most advanced technology and tools like cmTriage to support their evaluation of mammograms will lead to improved clinical outcomes, reduced healthcare costs and increased assurance that patients are receiving high quality and accurate clinical care.”

Related Links:
CureMetrix



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

17 Jul 2019
Machine Learning Can Predict Heart Disease Better Than Other Risk Models
A study conducted by researchers from the Yale School of Medicine has demonstrated that machine learning (ML), a type of artificial intelligence, performs better than conventional risk models at predicting heart attacks and other cardiac events when used along with a common heart scan.
Read More
17 Jul 2019
Global Portable X-Ray Devices Market to Reach USD 6.87 Billion by 2022
The global portable X-ray devices market grew at a compound annual growth rate (CAGR) of 8.8% from 2014 to 2018 to reach nearly USD 4.70 billion in 2018 and is projected to grow at a CAGR of 10% from 2018 to 2022 to reach almost USD 6.87 billion by 2022.
Read More
17 Jul 2019
Global Portable Ultrasound Devices Market to Reach USD 6.85 Billion by 2022
The global portable ultrasound devices market grew at a compound annual growth rate (CAGR) of 21% from 2014 to 2018 to reach nearly USD 3.03 billion in 2018 and is projected to grow at a CAGR of 22.6% from 2018 to 2022 to reach almost USD 6.85 billion by 2022.
Read More
17 Jul 2019
Agilent Technologies Expands Portfolio with Acquisition of BioTek Instruments
Agilent Technologies Inc., a global leader in the life sciences, diagnostics and applied chemical markets, has signed a definitive agreement to acquire privately-owned BioTek Instruments, which designs, manufactures, and distributes innovative life science instrumentation.
Read More
06 Jul 2019
ACR Expands Pilot Program Focused on AI and Radiology
Radiology professionals from seven renowned health care institutions will use the ACR AI-LAB to demonstrate the process of creating investigational artificial intelligence (AI) models from image data without the use of a programming language.
Read More
06 Jul 2019
Konica Minolta Offers AI-Based Cardiac Ultrasound Analysis
Konica Minolta Healthcare Americas Inc, a provider of medical diagnostic imaging and healthcare information technology, has announced a partnership with DiA Imaging Analysis, a provider of artificial intelligence (AI) powered ultrasound analysis solutions.
Read More
06 Jul 2019
VR and AI Drive Exponential Growth in Integrated Operating Rooms
The operating room (OR) is transforming from a seemingly simple box into a technology-powered, infection-free, and sleek surgical environment.
Read More
06 Jul 2019
AI-Based Image Reconstruction Solution Receives FDA Clearance
Canon Medical Systems USA, Inc. has received 510(k) clearance from the FDA for its new deep convolutional neural network (DCNN) image reconstruction technology.
Read More
06 Jul 2019
Bracco Imaging Acquires Blue Earth Diagnostics to Expand Portfolio
Bracco Imaging S.p.A. has signed a definitive agreement to acquire Blue Earth Diagnostics, a molecular imaging company.
Read More
Copyright © 2000-2019 TradeMed.com. All rights reserved. | Terms And Conditions